Table 2.
Cure proportions and years of life lost (YLLs) resulting from flexible parametric cure model.
| Variables | Proportion cured (95% C.I.) | p | Median age (IQR) | Median YLL (IQR) | p |
|---|---|---|---|---|---|
| Age | |||||
| <60 years | 19.0% (15.7, 22.7) | Ref. | 52 (47, 56) | 23.7 (21.1, 27.7) | Ref. |
| 60–70 years | 17.4% (13.9, 21.3) | 0.470 | 65 (62, 68) | 15.4 (13.1, 17.2) | 0.001 |
| 71–80 years | 17.2% (12.6, 22.5) | 0.510 | 74 (72, 77) | 9.4 (7.8, 10.6) | 0.001 |
| >80 years | 23.4% (10.6, 39.3) | 0.555 | 83 (81, 85) | 4.4 (3.5, 4.9) | 0.001 |
| Gender | |||||
| Male | 16.9% (14.2, 19.8) | Ref. | 61 (53, 69) | 17.4 (12.1, 22.7) | Ref. |
| Female | 23.0% (18.2, 28.1) | 0.014 | 65 (56, 73) | 16.6 (11.3, 22.7) | 0.144 |
| Year of diagnosis | |||||
| 2004–2008 | 14.7% (10.2, 20.2) | Ref. | 62 (53, 69) | 18.7 (13.6, 25.3) | Ref. |
| 2009–2013 | 17.5% (14.3, 21.1) | 0.346 | 61 (52, 69) | 18.0 (12.5, 23.9) | 0.206 |
| 2014–2018 | 20.5% (16.8, 24.4) | 0.056 | 62 (54, 70) | 16.1 (11.4, 21.7) | 0.001 |
| Hepatitis B | |||||
| Negative | 20.1% (16.8, 23.6) | Ref. | 67 (59, 73) | 14.7 (10.2, 19.9) | Ref. |
| Positive | 16.1% (13.0, 19.5) | 0.043 | 57 (50, 65) | 20.0 (15.0, 25.1) | 0.001 |
| Hepatitis C | |||||
| Negative | 19.3% (16.4, 22.3) | Ref. | 61 (52, 69) | 17.2 (12.3, 23.5) | Ref. |
| Positive | 14.4% (10.6, 18.8) | 0.033 | 64 (57, 74) | 16.6 (10.2, 22.4) | 0.001 |
| Alcohol | |||||
| Negative | 18.6% (15.9, 21.6) | Ref. | 61 (53, 70) | 17.6 (12.0, 23.4) | Ref. |
| Positive | 15.8% (10.9, 21.6) | 0.323 | 65 (58, 69) | 15.5 (12.1, 20.4) | 0.002 |
| ALBI grade | |||||
| 1 | 23.8% (19.8, 28.0) | Ref. | 60 (51, 69) | 16.5 (11.7, 22.6) | Ref. |
| 2 | 14.8% (12.0, 18.0) | 0.001 | 63 (56, 71) | 17.0 (12.2, 22.9) | 0.573 |
| 3 | 12.0% (6.8, 18.9) | 0.003 | 61 (53, 69) | 20.0 (13.5, 25.4) | 0.002 |
| Ablation technique | |||||
| RFA | 18.5% (15.8, 21.5) | Ref. | 61 (53, 69) | 17.6 (12.2, 23.4) | Ref. |
| MWA | 16.7% (11.7, 22.3) | 0.498 | 67 (59, 71) | 15.7 (11.5, 20.2) | 0.001 |
| Largest tumour size | |||||
| <2 cm | 26.9% (21.7, 32.3) | Ref. | 62 (53, 70) | 15.1 (10.6, 20.9) | Ref. |
| 2–3 cm | 19.2% (15.8, 23.0) | 0.007 | 61 (54, 70) | 17.4 (12.0, 22.5) | 0.006 |
| 3.1–5 cm | 12.7% (9.5, 16.4) | 0.001 | 63 (55, 70) | 17.5 (12.5, 23.8) | 0.001 |
| >5 cm | 4.6% (1.9, 9.4) | 0.001 | 56 (48, 67) | 23.7 (16.2, 31.2) | 0.001 |
| Tumour number | |||||
| Single | 20.8% (17.8, 24.0) | Ref. | 62 (53, 70) | 16.7 (11.8, 22.4) | Ref. |
| 2 or 3 nodules | 11.5% (8.1, 15.5) | 0.001 | 62 (55, 70) | 18.3 (12.2, 24.2) | 0.037 |
| 4+ nodules | 2.5% (0.7, 6.3) | 0.001 | 63 (57, 69) | 19.5 (14.6, 24.6) | 0.012 |
| Very-early stage | |||||
| Within | 30.9% (24.9, 37.1) | Ref. | 61 (53, 70) | 14.5 (9.9, 20.4) | Ref. |
| Beyond | 15.4% (12.8, 18.2) | 0.001 | 62 (54, 70) | 17.7 (12.3, 23.7) | 0.001 |
| Milan criteria | |||||
| Within | 20.7% (17.7, 23.8) | Ref. | 62 (54, 70) | 16.5 (11.5, 22.2) | Ref. |
| Beyond | 5.2% (3.0, 8.1) | 0.001 | 60 (52, 68) | 20.8 (14.5, 26.9) | 0.001 |
Variables affecting cure proportion entered into the multivariable flexible parametric model. Variables affecting YLLs were used through the generalised linear model to produce approximated YLLs values. Very-early stage and Milan criteria were not entered in the models because their components (size and number) were already retained.